Document:

SPREAD ACCOUNT SUPPLEMENT

  
 Exhibit 10.4

  
 EXECUTION COPY 
  
 SERIES 2005-C-F SUPPLEMENT 
 TO SPREAD ACCOUNT AGREEMENT 
  
 Dated as of August 17, 2005 
  
 This Series 2005-C-F Supplement (this “Supplement”), dated as of August 17, 2005, is by and among FINANCIAL SECURITY ASSURANCE INC.
(“Financial Security”), AFS FUNDING TRUST (“Funding Trust”), WELLS FARGO BANK, NATIONAL ASSOCIATION, in its capacities as Trustee and Trust Collateral Agent under the Indenture referred to below (in such capacity, the
“Trustee”) and as Collateral Agent under the Spread Account Agreement dated as of December 1, 1994, as amended and restated as of May 11, 1998, as further amended and restated as of September 10, 2003, among the parties thereto (the
“Master Agreement”), as the same may be further amended, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms thereof. Capitalized terms used in this Supplement and not otherwise
specifically defined have the meaning given such terms in the Master Agreement. 
  
 WITNESSETH: 
  
 WHEREAS, the parties hereto have executed the Master Agreement, which contemplates and provides for the execution and delivery of individual Series
Supplements with respect to Series of notes or certificates issued pursuant to an Indenture or a Pooling and Servicing Agreement, for the purpose of identifying, describing, and pledging Collateral related to a particular Series of notes or
certificates; 
  
 WHEREAS, AmeriCredit Automobile Receivables
Trust 2005-C-F (the “Series 2005-C-F Trust”) has been formed pursuant to a Trust Agreement dated as of August 9, 2005, as amended and restated as of August 17, 2005, between AFS Funding Trust and Wilmington Trust Company, as Owner Trustee
(the “Series 2005-C-F Trust Agreement”); 
  
 WHEREAS,
pursuant to a Sale and Servicing Agreement dated as of August 17, 2005 among AmeriCredit Financial Services, Inc., as Servicer, Funding Trust, as Seller and Wells Fargo Bank, National Association, as Backup Servicer and Trust Collateral Agent (the
“2005-C-F Sale and Servicing Agreement”), Funding Trust is selling to the Series 2005-C-F Trust all of its right, title and interest in and to certain receivables and certain other trust property; and 
  
 WHEREAS, the Series 2005-C-F Trust is issuing the Series 2005-C-F Notes (as
defined herein) pursuant to an Indenture dated as of August 17, 2005 between the Series 2005-C-F Trust and Wells Fargo Bank, National Association, as Trustee and Trust Collateral Agent (the “2005-C-F Indenture”); 
  
 WHEREAS, the Series 2005-C-F Trust has agreed to pay the Series 2005-C-F
Credit Enhancement Fee to Funding Trust in consideration of the obligations of Funding Trust pursuant hereto (such obligations forming part of the Series 2005-C-F Insurer Secured Obligations). The Series 2005-C-F Insurer Secured Obligations form
part of the 

 
consideration to Financial Security for its issuance of the Series 2005-C-F Policy (as defined herein). 
  
 NOW, THEREFORE, it is hereby agreed by and among the parties hereto as
follows: 
  
 ARTICLE I 
  
 AGREEMENT 
  
 Section 1.01. Definitions. Each term used but not defined herein shall have the meaning assigned to such term in the
Master Agreement, the AmeriCredit 2005-C-F Letter Agreement (as defined below) or in the Series 2005-C-F Sale and Servicing Agreement (as defined below). 
  
 “Accelerated Payment Termination Date” means the earlier of the Distribution Date (as such term is defined in the Series 2005-C-F Sale and
Servicing Agreement) on which (A) the principal balance of the Series 2005-C-F Class A-1 Notes is reduced to zero or (B) the Accelerated Payment Amount Shortfall (as such term is defined in the Series 2005-C-F Sale and Servicing Agreement) equals
zero. 
  
 “AmeriCredit 2005-C-F Letter Agreement” means
that certain letter agreement dated as of August 30, 2005 among Financial Security, Funding Trust, AmeriCredit Automobile Receivables Trust 2005-C-F, AmeriCredit Corp., AmeriCredit Financial Services, Inc. and the Trustee, as the same may be
amended, supplemented or otherwise modified in accordance with the terms thereof. 
  
 “April–October Determination Date” shall mean, with respect to Series 2005-C-F, a Determination Date occurring during the months of April, May, June, July, August, September or October. 
  
 “Cumulative Default Rate” shall mean, with respect to Series
2005-C-F and with respect to any Determination Date, the fraction, expressed as a percentage, the numerator of which is equal to the Principal Balance of all Receivables which became Defaulted Receivables since the Initial Cutoff Date as of the
related Accounting Date and the denominator of which is equal to the Original Pool Balance. 
  
 “Cumulative Default Test Failure” shall mean, with respect to Series 2005-C-F, the Cumulative Default Rate shall be equal to or greater than: (A) 3.31%, with respect to any Determination Date occurring prior
to or during the 3rd calendar month succeeding the Series 2005-C-F Closing Date, (B) 5.45%, with respect to any Determination Date occurring after the 3rd, and prior to or during the 6th, calendar month succeeding the Series 2005-C-F Closing Date,
(C) 7.72%, with respect to any Determination Date occurring after the 6th, and prior to or during the 9th, calendar month succeeding the Series 2005-C-F Closing Date, (D) 9.37%, with respect to any Determination Date occurring after the 9th, and
prior to or during the 12th, calendar month succeeding the Series 2005-C-F Closing Date, (E) 11.24%, with respect to any Determination Date occurring after the 12th, and prior to or during the 15th, calendar month succeeding the 

  

 2 

 
Series 2005-C-F Closing Date, (F) 13.59%, with respect to any Determination Date occurring after the 15th, and prior to or during the 18th, calendar month
succeeding the Series 2005-C-F Closing Date, (G) 15.93%, with respect to any Determination Date occurring after the 18th, and prior to or during the 21st, calendar month succeeding the Series 2005-C-F Closing Date, (H) 17.33%, with respect to any
Determination Date occurring after the 21st, and prior to or during the 24th, calendar month succeeding the Series 2005-C-F Closing Date, (I) 19.21%, with respect to any Determination Date occurring after the 24th, and prior to or during the 27th,
calendar month succeeding the Series 2005-C-F Closing Date, (J) 20.61%, with respect to any Determination Date occurring after the 27th, and prior to or during the 30th, calendar month succeeding the Series 2005-C-F Closing Date, (K) 22.25%, with
respect to any Determination Date occurring after the 30th, and prior to or during the 33rd, calendar month succeeding the Series 2005-C-F Closing Date, (L) 23.42%, with respect to any Determination Date occurring after the 33rd, and prior to or
during the 36th, calendar month succeeding the Series 2005-C-F Closing Date, (M) 24.59%, with respect to any Determination Date occurring after the 36th, and prior to or during the 39th, calendar month succeeding the Series 2005-C-F Closing Date,
(N) 25.30%, with respect to any Determination Date occurring after the 39th, and prior to or during the 42nd, calendar month succeeding the Series 2005-C-F Closing Date and (O) 26.00%, with respect to any Determination Date occurring after the 42nd
calendar month succeeding the Series 2005-C-F Closing Date. 
  
 “Cumulative Net Loss Rate” shall mean, with respect to Series 2005-C-F and with respect to any Determination Date, the fraction, expressed as a percentage, the numerator of which is equal to the sum of (a) Net Losses for such
Determination Date plus (b) 50% of the Principal Balance of all Receivables with respect to which 10% or more of a Scheduled Payment has become 91 or more days delinquent (not including Receivables included under the definition of Net Losses in
clause (a) above) as of the related Accounting Date and the denominator of which is equal to the Original Pool Balance. 
  
 “Cumulative Net Loss Test Failure” shall mean, with respect to Series 2005-C-F, the Cumulative Net Loss Rate shall be equal to or greater than:
(A) 1.99%, with respect to any Determination Date occurring prior to or during the 3rd calendar month succeeding the Series 2005-C-F Closing Date, (B) 3.22%, with respect to any Determination Date occurring after the 3rd, and prior to or during the
6th, calendar month succeeding the Series 2005-C-F Closing Date, (C) 4.50% with respect to any Determination Date occurring after the 6th, and prior to or during the 9th, calendar month succeeding the Series 2005-C-F Closing Date, (D) 5.78%, with
respect to any Determination Date occurring after the 9th, and prior to or during the 12th, calendar month succeeding the Series 2005-C-F Closing Date, (E) 7.49%, with respect to any Determination Date occurring after the 12th, and prior to or
during the 15th, calendar month succeeding the Series 2005-C-F Closing Date, (F) 8.66%, with respect to any Determination Date occurring after the 15th, and prior to or during the 18th, calendar month succeeding the Series 2005-C-F Closing Date, (G)
10.30%, with respect to any Determination Date occurring after the 18th, and prior to or during the 21st, calendar month succeeding the Series 2005-C-F Closing Date, (H) 11.24%, with respect to any Determination Date occurring after the 21st, and
prior to or during the 24th, calendar month succeeding the Series 2005-C-F Closing Date, (I) 11.94%, with respect to any 

  

 3 

 
Determination Date occurring after the 24th, and prior to or during the 27th, calendar month succeeding the Series 2005-C-F Closing Date, (J) 12.88%, with
respect to any Determination Date occurring after the 27th, and prior to or during the 30th, calendar month succeeding the Series 2005-C-F Closing Date, (K) 13.81%, with respect to any Determination Date occurring after the 30th, and prior to or
during the 33rd, calendar month succeeding the Series 2005-C-F Closing Date, (L) 14.28%, with respect to any Determination Date occurring after the 33rd, and prior to or during the 36th, calendar month succeeding the Series 2005-C-F Closing Date and
(M) 14.75%, with respect to any Determination Date occurring after the 36th calendar month succeeding the Series 2005-C-F Closing Date. 
  
 “Delinquency Test Failure” shall mean, (A) with respect to Series 2005-C-F and with respect to any April-October Determination Date, the
arithmetic average of the Delinquency Ratio for such Determination Date and the two immediately preceding Determination Dates is equal to or greater than 4.0%; provided, however, in the event that the OC Percentage is equal to or
greater than the Target OC Percentage on any Determination Date occurring subsequent to the twelfth Determination Date after the Series 2005-C-F Closing Date, the percentage referred to in the previous clause for such April-October Determination
Date and each Determination Date thereafter shall be deemed to be 5.0%; provided, further, in the event that the OC Percentage is equal to or greater than the Target OC Percentage on any Determination Date occurring subsequent to the
twenty-fourth Determination Date after the Series 2005-C-F Closing Date, the percentage referred to in the previous clause for such April-October Determination Date and each Determination Date thereafter shall be deemed to be 5.50%; provided,
further, in the event that the OC Percentage is equal to or greater than the Target OC Percentage on any Determination Date occurring subsequent to the thirtieth Determination Date after the Series 2005-C-F Closing Date, the percentage
referred to in the previous clause for such April-October Determination Date and each Determination Date thereafter shall be deemed to be 6.0%; and provided, further, in the event that the OC Percentage is equal to or greater than the
Target OC Percentage on any Determination Date occurring subsequent to the thirty-sixth Determination Date after the Series 2005-C-F Closing Date, the percentage referred to in the previous clause for such April-October Determination Date and each
Determination Date thereafter shall be deemed to be 6.75%; or (B) with respect to Series 2005-C-F and with respect to any November-March Determination Date, the arithmetic average of the Delinquency Ratio for such Determination Date and the two
immediately preceding Determination Dates is equal to or greater than 4.25%; provided, however, in the event that the OC Percentage is equal to or greater than the Target OC Percentage on any Determination Date occurring subsequent to
the twelfth Determination Date after the Series 2005-C-F Closing Date, the percentage referred to in the previous clause for such November-March Determination Date and each Determination Date thereafter shall be deemed to be 5.25%; provided,
further, in the event that the OC Percentage is equal to or greater than the Target OC Percentage on any Determination Date occurring subsequent to the twenty-fourth Determination Date after the Series 2005-C-F Closing Date, the percentage
referred to in the previous clause for such November-March Determination Date and each Determination Date thereafter shall be deemed to be 5.75%; provided, further, in the event that the OC Percentage is equal to or greater than the
Target OC Percentage on any Determination Date occurring 

  

 4 

 
subsequent to the thirtieth Determination Date after the Series 2005-C-F Closing Date, the percentage referred to in the previous clause for such
November-March Determination Date and each Determination Date thereafter shall be deemed to be 6.25%; and provided, further, in the event that the OC Percentage is equal to or greater than the Target OC Percentage on any Determination
Date occurring subsequent to the thirty-sixth Determination Date after the Series 2005-C-F Closing Date, the percentage referred to in the previous clause for such November-March Determination Date and each Determination Date thereafter shall be
deemed to be 7.00%. 
  
 “Floor Amount” shall
mean, with respect to Series 2005-C-F and with respect to any Determination Date, the greater of (A) $100,000 and (B) the lesser of (i) the Note Balance and (ii) 2.0% of the Original Pool Balance. 
  
 “Note Balance” shall mean, with respect to any Determination Date,
the sum of the aggregate principal balance of the Notes with respect to such Determination Date after giving effect to all distributions on the Notes on the related Distribution Date. 
  
 “November–March Determination Date” shall mean, with respect to Series 2005-C-F, a Determination Date
occurring during the months of November, December, January, February or March. 
  
 “OC Level” shall mean 13.5%; provided, however, if each of the “Step-Down Conditions” set forth in the AmeriCredit 2005-C-F Letter Agreement are satisfied on a Determination Date
preceding the Distribution Date set forth in the following table, the OC Level shall be reduced to the amount set forth with respect to such Distribution Date in the following table; provided, further, however, that if any of
such “Step Down Conditions” are not satisfied with respect to any Distribution Date in the following table, the OC Level shall not be reduced on such Distribution Date and will not be subject to reduction or further reduction, as
applicable, until the next Distribution Date set forth in the following table (if any): 
  

				
	 Distribution Date occurring in:

	  	OC Level

	 
	 18th calendar month
	  	12.5	%
		
	 24th calendar month
	  	11.5	%
		
	 30th calendar month
	  	10.5	%

  
 “OC
Percentage” shall mean, with respect to Series 2005-C-F and with respect to any Determination Date, the sum of (i) the percentage equivalent of a fraction the numerator of which is equal to the excess, if any, of (A) the Aggregate Principal
Balance as of such Determination Date over (B) the Note Balance minus the Pre-Funded Amount as of such Determination Date and the denominator of which is equal to the Aggregate Principal Balance as of such Determination Date, and (ii) the
percentage equivalent of a fraction the numerator of which is equal to the amount on deposit in the Series 2005-C-F Spread Account as of such Determination Date (after giving effect to any withdrawals from the Series 2005-C-F Spread Account to be
made on the related Distribution Date) 

  

 5 

 
and the denominator of which is equal to the Aggregate Principal Balance as of such Determination Date. 
  
 “Pre-Funded Amount” has the meaning specified in the Series
2005-C-F Sale and Servicing Agreement. 
  
 “Requisite
Amount” shall mean, as of any Determination Date, (A) if no Trigger Event and no Insurance Agreement Event of Default shall exist as of such Determination Date, the sum of (a) the Floor Amount with respect to such Determination Date and (b) the
Spread Account Shortfall, if any, with respect to such Determination Date; (B) if a Trigger Event shall exist as of such Determination Date and no Insurance Agreement Event of Default shall have occurred as of such Determination Date, the sum of (i)
8.5% of the Aggregate Principal Balance with respect to such Determination Date and (ii) the Spread Account Shortfall, if any, with respect to such Determination Date; or (C) if an Insurance Agreement Event of Default shall have occurred as of such
Determination Date, an unlimited amount. 
  
 “Series 2005-C-F
Credit Enhancement Fee” means the amount distributable on each Distribution Date pursuant to Sections 5.7(b)(vi) and (viii) of the Series 2005-C-F Sale and Servicing Agreement. 
  
 “Series 2005-C-F Insurance Agreement” means the Insurance and Indemnity Agreement dated as of August 17, 2005,
among Financial Security, the Series 2005-C-F Trust, AmeriCredit Financial Services, Inc., AmeriCredit Corp. and Funding Trust. 
  
 “Series 2005-C-F Insurer Secured Obligations” means all amounts and obligations which may at any time be owed to or on behalf of Financial
Security (or any agents, accountants or attorneys for Financial Security) under the Series 2005-C-F Insurance Agreement or under any Transaction Document (as defined in the Series 2005-C-F Insurance Agreement), regardless of whether such amounts are
owed now or related to such Series in the future, whether liquidated or unliquidated, contingent or non-contingent. 
  
 “Series 2005-C-F Notes” means the $182,000,000 Class A-1 3.8445% Asset Backed Notes, $271,000,000 Class A-2 4.31% Asset Backed Notes,
$356,000,000 Class A-3 4.47% Asset Backed Notes and $291,000,000 Class A-4 4.63% Asset Backed Notes, issued pursuant to the Series 2005-C-F Indenture. 
  
 “Series 2005-C-F Policy” means the financial guaranty insurance policies issued by Financial Security with respect to each of the Series
2005-C-F Notes pursuant to the Series 2005-C-F Insurance Agreement. 
  
 “Series 2005-C-F Sale and Servicing Agreement” means the Sale and Servicing Agreement, dated as of August 17, 2005, among AmeriCredit Automobile Receivable Trust 2005-C-F, as Issuer, AFS Funding Trust, as Seller, AmeriCredit
Financial Services, Inc., as Servicer and Wells Fargo Bank, National Association, a national association, as Backup Servicer and Trust Collateral Agent. 
  

 6 

 “Target OC Percentage” shall mean, with respect to Series 2005-C-F and with respect to any
Determination Date, the sum of (i) the percentage equivalent of a fraction the numerator of which is equal to the Floor Amount as of such Determination Date and the denominator of which is equal to the Aggregate Principal Balance as of such
Determination Date, and (ii) the percentage equivalent of a fraction the numerator of which is equal to the excess, if any, of (A) the Aggregate Principal Balance as of such Determination Date over (B) the Required Pro Forma Note Balance as of such
Determination Date and the denominator of which is equal to the Aggregate Principal Balance as of such Determination Date. 
  
 “Trigger Event” shall mean, with respect to Series 2005-C-F and as of a Determination Date, the occurrence of any of the following: 

 

	 	(i)	the occurrence of a Cumulative Net Loss Test Failure; 

  

	 	(ii)	the occurrence of a Delinquency Test Failure; or 

  

	 	(iii)	the occurrence of a Cumulative Default Test Failure. 

  
 Section 1.02. Series 2005-C-F Credit Enhancement Fee. The Series 2005-C-F Sale and Servicing Agreement provides for the payment to Funding Trust of
the Series 2005-C-F Credit Enhancement Fee, to be paid to Funding Trust by distribution of such amounts to the Collateral Agent for deposit and distribution pursuant to this Agreement. Funding Trust hereby agrees that payment of the Series 2005-C-F
Credit Enhancement Fee in the manner and subject to the conditions set forth herein and in the Series 2005-C-F Sale and Servicing Agreement is adequate consideration and the exclusive consideration to be received by Funding Trust for the obligations
of Funding Trust pursuant hereto (including, without limitation, the transfer by Funding Trust to the Collateral Agent of the Series 2005-C-F Spread Account Initial Deposit) and pursuant to the Series 2005-C-F Insurance Agreement. Funding Trust
hereby agrees with the Trustee and with Financial Security that payment of the Series 2005-C-F Credit Enhancement Fee to Funding Trust is expressly conditioned on subordination of the Series 2005-C-F Credit Enhancement Fee to payments on the Notes
and the Certificates of any Series, payments of amounts due to Financial Security and the other obligations of the Trusts, in each case to the extent provided in the section governing distributions in the related Sale and Servicing Agreement or
Pooling and Servicing Agreement, as applicable, and Section 3.03 of the Master Agreement, and the Security Interest of the Secured Parties in the Series 2005-C-F Collateral is intended to effect and enforce such subordination and to provide security
for the Series 2005-C-F Secured Obligations and subject to the terms hereof the Secured Obligations with respect to other Series. 
  
 Section 1.03. Grant of Security Interests by Funding Trust. 
  
 (a) In order to secure the performance of the Secured Obligations related to Series 2005-C-F, and the Secured Obligations
related to other Series to the extent provided in the Master Agreement, Funding Trust hereby pledges, assigns, grants, transfers and conveys to Wells Fargo Bank, National Association, as Collateral Agent, on 

  

 7 

 
behalf of and for the benefit of the Secured Parties to secure such Secured Obligations, a Lien on and security interest in (which Lien and security interest
is intended to be prior to all other Liens), all of its right, title and interest in and to the following (all being collectively referred to herein as the “Series 2005-C-F Collateral” and constituting Collateral under the Master
Agreement): 
  
 (i) the Series 2005-C-F Credit
Enhancement Fee and all rights and remedies that Funding Trust may have to enforce payment of the Series 2005-C-F Credit Enhancement Fee whether under the Series 2005-C-F Sale and Servicing Agreement or otherwise; 
  
 (ii) the Series 2005-C-F Spread Account (the “Series
2005-C-F Spread Account”) as established pursuant to Section 3.01 of the Master Agreement (including, without limitation, the Series 2005-C-F Spread Account Initial Deposit (as defined below), the Series 2005-C-F Subsequent Spread Account
Deposits and all additional monies, checks, securities, investments and other items or documents at any time held in or evidencing any such accounts); 
  
 (iii) all of Funding Trust’s right, title and interest in and to investments made with proceeds of the property described in clauses
(i) and (ii) above, including investments made with amounts on deposit in the Series 2005-C-F Spread Account; 
  
 (iv) to the extent recourse is provided under the Master Agreement to Collateral related to other Series (as such Collateral is described
in the applicable Series Supplement(s) related thereto), such Collateral; and 
  
 (v) all distributions, revenues, products, substitutions, benefits, profits and proceeds, in whatever form, of any of the foregoing. 
  
 (b) In order to effectuate the provisions and purposes of this Supplement, including for the purpose of perfecting the
security interests granted hereunder, Funding Trust represents and warrants that it has, prior to the execution of this Supplement, executed and filed an appropriate Uniform Commercial Code financing statement in Delaware sufficient to assure that
the Collateral Agent, as agent for the Secured Parties, has a first priority perfected security interest in all Series 2005-C-F Collateral which can be perfected by the filing of a financing statement or has delivered to Financial Security a legal
opinion acceptable to Financial Security to the effect that no filings are required to perfect the security interests granted hereunder. 
  
 Section 1.04. The parties hereto acknowledge and agree that the Spread Account Initial Deposit comprising part of the Series 2005-C-F Collateral shall be
in the amount of $18,000,099.85 (the “Series 2005-C-F Spread Account Initial Deposit”). Funding Trust and the Collateral Agent confirm that concurrently with the execution and delivery of this Supplement such amount has been deposited by
Funding Trust with the Collateral Agent for deposit into the Series 2005-C-F Spread Account. The parties hereto agree that on each Subsequent Transfer Date, the Series 2005-C-F Trust will, pursuant to 

  

 8 

 
Section 2.2 of the Series 2005-C-F Sale and Servicing Agreement, deliver on behalf of Funding Trust, the Subsequent Spread Account Deposit for such
Subsequent Transfer Date to the Collateral Agent. 
  
 Section
1.05. Wells Fargo Bank, National Association, hereby undertakes and agrees to act as “securities intermediary” (as such term is defined in Section 8-102 (a)(14) of the Uniform Commercial Code as in effect in the State of New York (the
“New York UCC”)). In such capacity (Wells Fargo Bank, National Association, in such capacity being herein sometimes referred to as the “Securities Intermediary”) and in accordance with Section 3.01 of the Master Agreement, the
Securities Intermediary has established account number 18221703 in the name of Wells Fargo Bank, National Association, as Trustee and Collateral Agent which account is the account referred to herein as the “Series 2005-C-F Spread Account.”
The Security Intermediary represents, warrants, acknowledges and agrees that: 
  
 (a) It shall not change the name or account number of the Series 2005-C-F Spread Account without the prior written consent of the Collateral Agent; 
  
 (b) All securities or other property underlying any financial assets deposited in or credited to the Series 2005-C-F Spread
Account shall be registered in the name of the Securities Intermediary or the Collateral Agent or in blank or credited to another securities account or accounts maintained in the name of the Securities Intermediary, and in no case shall any
financial asset deposited in or credited to the Series 2005-C-F Spread Account be registered in the name of Funding Trust except to the extent the foregoing have been specially indorsed to the Securities Intermediary in blank; 
  
 (c) All property delivered to the Securities Intermediary pursuant to the
Master Agreement and this Supplement for deposit in or credit to the Series 2005-C-F Spread Account shall be promptly credited to the Series 2005-C-F Spread Account; 
  
 (d) The Series 2005-C-F Spread Account is a “securities account” as such term is defined in Section 8-501(a) of
the New York UCC, and the Securities Intermediary agrees that each item of property (whether investment property, financial asset, security, instrument or cash) deposited in or credited to the Series 2005-C-F Spread Account shall be treated as a
“financial asset” within the meaning of Section 8-102(a)(9) of the New York UCC and that, subject to the terms of the Master Agreement and this Supplement, the Securities Intermediary will treat the Collateral Agent as entitled to exercise
the rights that comprise any financial asset deposited in or credited to such Account; and 
  
 (e) If at any time the Securities Intermediary shall receive any order from the Collateral Agent directing transfer or redemption of any financial asset relating to the Series 2005-C-F Spread Account, the Securities
Intermediary shall comply with such entitlement order without further consent by Funding Trust or any other person. 
  
 Without limiting the generality of Section 2.04 this Supplement, the parties agree that both this Supplement and the Series 2005-C-F Spread Account shall
be governed by the laws of the State of New York. Regardless of any provision in any other agreement, 

  

 9 

 
for purposes of the New York UCC, New York shall be deemed to be the Securities Intermediary’s jurisdiction and the Series 2005-C-F Spread Account (as
well as all of the securities entitlements related thereto) shall be governed by the laws of the State of New York. 
  
 ARTICLE II 
  
 MISCELLANEOUS 
  
 Section 2.01. This Supplement may be
executed in multiple counterparts, each of which shall constitute an original and all of which when taken together shall constitute one instrument. 
  
 Section 2.02. The covenants, representations and agreements provided for in the Master Agreement are hereby in all respects ratified, confirmed and
approved by the parties hereto and made applicable to this Supplement. 
  
 Section 2.03. Further Assurances. Each party hereto shall take such action and deliver such instruments to any other party hereto, in addition to the actions and instruments specifically provided herein, as may be reasonably
requested or required to effectuate the purpose or provisions of this Supplement or to confirm or perfect any transaction described or contemplated herein. 
  
 Section 2.04. Governing Law. THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH, AND THIS AGREEMENT AND ALL MATTERS ARISING OUT OF OR RELATING IN
ANY WAY TO THIS AGREEMENT SHALL BE GOVERNED BY, THE LAW OF THE STATE OF NEW YORK. 
  

 10 

  
 IN WITNESS WHEREOF, each of
the parties hereto has executed this Supplement by their respective duly authorized officers or agents, as of the date first written above. 
  

					
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee
		
	By:	 	 /s/ Marianna C. Stershic

	 	 	 Name:
	 	 Marianna C. Stershic

	 	 	 Title:
	 	 Vice President

	
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Collateral Agent
		
	By:	 	 /s/ Marianna C. Stershic

	 	 	 Name:
	 	 Marianna C. Stershic

	 	 	 Title:
	 	 Vice President

	
	FINANCIAL SECURITY ASSURANCE INC.
		
	By:	 	 /s/ Ravi Gandhi

	 	 	Authorized Officer
	
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Securities Intermediary
		
	By:	 	 /s/ Marianna C. Stershic

	 	 	 Name:
	 	 Marianna C. Stershic

	 	 	 Title:
	 	 Vice President

	
	AFS FUNDING TRUST
	
	By: AmeriCredit Financial Services, Inc., as Administrator
		
	By:	 	 /s/ J. Michael May

	 	 	 Name:
	 	 J. Michael May

	 	 	 Title:
	 	 Senior Vice President, General Counsel

  
 [SPREAD ACCT SUPP
SIG PAGE]Amendment to Collaboration and License Agreement

 Exhibit 10.1 
  
 AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT BY AND 
  
 BETWEEN ASTELLAS US LLC (FORMERLY FUJISAWA HEALTHCARE, INC.) 
  
 AND 
  
 CV THERAPEUTICS, INC. 
  
 August 30, 2005 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 AMENDMENT TO 
 COLLABORATION AND LICENSE AGREEMENT 
  
 This Amendment (“Amendment”) is entered into, effective as of August 30, 2005 (the “Amendment Effective Date”), by and between Astellas US LLC (“Astellas”, successor-in-interest to
Fujisawa Healthcare, Inc., the original signatory to the Agreement defined below), and CV Therapeutics, Inc. (“CVT”) (Astellas and CVT being individually referred to herein as a “Party” and collectively as the
“Parties”), with reference to the following facts and circumstances: 
  
 WHEREAS, CVT and Fujisawa Healthcare, Inc. (“FHI”, predecessor-in-interest to Astellas) entered into that certain Collaboration and License Agreement dated as of July 10, 2000 (the “Agreement”);

  
 WHEREAS, in connection with a merger involving FHI, the
Agreement has been assigned to Astellas with CVT’s consent; and 
  
 WHEREAS, the Parties wish to clarify certain understandings respecting the Agreement, as expressly set forth in this Amendment, 
  
 NOW THEREFORE, in consideration of the mutual covenants exchanged, the Parties agree as follows: 
  
 1. Definitions. Except as expressly set forth herein, all capitalized terms used
herein and not otherwise defined shall be as defined in the Agreement. 
  
 2.
References. Effective as of April 1, 2005, CVT has consented to the assignment of the Agreement to Astellas, and Astellas has agreed to assume FHI’s rights and obligations under the Agreement. In connection therewith, all references in
the Agreement or this Amendment to Fujisawa Healthcare, Inc. or FHI are deemed to be references to Astellas. In addition, in the Agreement or this Amendment, all references to the Agreement shall be deemed to mean the Agreement as amended by this
Amendment. 
  
 3. Designated Patents. The list of Designated Patents set
forth in Schedule 1.10 of the Agreement is hereby replaced with the attached restated Schedule 1.10, which is incorporated herein.  
  
 4. Development Costs. In Section 1.11 of the Agreement, the definition of Development Costs in the Agreement is hereby amended and restated as follows: 

  
 “1.11 “Development Costs” means the
directly allocable out-of-pocket costs of development (but not capital investment costs), plus FTE Charges, incurred by CVT or FHI in accordance with Section 3.4(a) in conducting their respective work under this Agreement and the Development Program
in accordance with the 

 Development Plan, including, without limitation, costs associated with preparation and filing of
submissions for Regulatory Approvals for Licensed Compounds and/or Licensed Products. Development Costs do not include any costs associated with marketing, sales, promotion or distribution of Licensed Compounds and/or Licensed Products. With respect
to the manufacture and supply of Licensed Compounds and/or Licensed Products, Development Costs shall only include (i) the directly allocable out-of-pocket costs (but not capital investment costs), plus FTE Charges, incurred by CVT in conducting CVT
Manufacturing Activities under Section 3.4(a) up to and in connection with FDA approval of the first NDA for the first Licensed Product hereunder, and (ii) the directly allocable out-of-pocket costs (but not capital investment costs), plus FTE
Charges, incurred by FHI in conducting FHI Manufacturing Activities under Section 3.4(a) up to and in connection with FDA approval of the first NDA for the first Licensed Product hereunder, and the Parties specifically agree that the costs and FTE
Charges specifically included within Development Costs under the foregoing clauses (i) and (ii) shall include all directly allocable out-of-pocket costs (but not capital investment costs), plus FTE Charges, incurred by CVT or by FHI in preparing,
conducting or completing the Validation Package, irrespective of whether the timing of completion of some of said validation activities relating to the first NDA for the first Licensed Product is before or after the receipt of FDA approval of the
first NDA for the first Licensed Product. In any event, with respect to the manufacture and supply of Licensed Compounds and Licensed Products, Development Costs shall not include the costs of producing any Licensed Compounds and/or Licensed
Products which could be sold commercially as determined by the Management Committee. In no event shall such directly allocable out-of-pocket costs include any costs which are otherwise included in FTE Charges.” 
  
 5. FHI Development Technology. Section 1.17 of the Agreement is hereby amended and
restated as follows: 
  
 “1.17 “FHI Development
Technology” means any and all (a) Collaborative Clinical Data in the FHI Field; (b) FHI Clinical Data in the Development Field; (c) FHI Manufacturing Technology in the Development Field; (d) Improvements to FHI Clinical Data developed
solely by FHI in the Development Field; (e) FHI’s joint interest in any and all Improvements to the Collaborative Clinical Data developed jointly by FHI and CVT in the FHI Field; and (f) Improvements to the FHI Manufacturing Technology
developed by FHI (on its own or with CVT or Third Parties but which are Controlled by FHI) in the Development Field.” 
  
 6. Licensed Compounds. Section 1.29 of the Agreement is hereby amended and restated as follows: 
  
 “1.29 “Licensed Compounds” means the compounds known as CVT 3146, or regadenoson, and [*], the
chemical names and structures of which are set forth in Schedule 1.29 hereto.” 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 In addition, a new Schedule 1.29, attached hereto, is hereby added to the Agreement and incorporated herein.

  
 7. Net Sales. The introductory paragraph of Section 1.37 of the
Agreement is hereby amended and restated as follows: 
  
 “1.37 “Net Sales” means, collectively, the gross invoiced sales price of all Licensed Products sold by FHI (or for the purposes of Section 3.7(e) and Section 8.2(b) only, CVT or its Affiliates or sublicensees), or its
Affiliates or its Sublicensees to Third Party purchasers after deduction of the following items whether currently in effect or which become effective during the Term as they pertain to the Licensed Products:” 
  
 In addition, the final paragraph of Section 1.37 of the Agreement is hereby amended and
restated as follows: 
  
 “No deductions shall be made from
Net Sales for commissions paid to individuals whether they are with independent sales agencies or are regularly employed by FHI (or for the purposes of Section 3.7(e) and Section 8.2(b) only, CVT or its Affiliates or sublicensees), and/or its
Affiliates or its Sublicensees and are on its or their payroll, or for the cost of collections. Licensed Products shall be considered “sold” when billed out or invoiced. Sales by FHI (or for the purposes of Section 3.7(e) and Section
8.2(b) only, CVT or its Affiliates or sublicensees), or its Affiliates or Sublicensees of a Licensed Product to a Third Party distributor of such Licensed Product in any given country shall be considered a sale to a Third Party purchaser. Sale or
transfer to an Affiliate or Sublicensee for re-sale by such Affiliate or Sublicensee shall not be considered a sale for the purpose of this provision, but the resale by such Affiliate or Sublicensee to a Third Party shall be a sale for such
purposes.” 
  
 8. Cost of Goods. A new Section 1.53 of the Agreement
is hereby added as follows: 
  
 “1.53 “Cost of
Goods” shall have the meaning ascribed in Section 3.4(c)(ii).” 
  
 9. CVT Manufacturing Contracts. A new Section 1.54 of the Agreement is hereby added as follows: 
  
 “1.54 “CVT Manufacturing Contracts” shall have the meaning ascribed in Section 3.4(e).” 

 10. FHI Manufacturing Contracts. A new Section 1.55 of the Agreement is hereby added as follows: 
  
 “1.55 “FHI Manufacturing Contracts” shall have the
meaning ascribed in Section 3.4(d).” 
  
 11. FHI Manufacturing
Technology. A new Section 1.56 of the Agreement is hereby added as follows: 
  
 “1.56 “FHI Manufacturing Technology” means Information and Improvements Controlled by FHI as of the Effective Date or during the Term that (i) are necessary or useful for the commercial
manufacture of Licensed Compounds and/or Licensed Products; and (ii) specifically result from the CVT Manufacturing Activities or FHI Manufacturing Activities under the Agreement, including any such Information or Improvements Controlled by FHI and
arising under any CVT Manufacturing Contracts or FHI Manufacturing Contracts, or contained in the Validation Package, provided that in any case with respect to such CVT Manufacturing Activities or FHI Manufacturing Activities (to include work on the
Validation Package), such activities are Paid by CVT. For avoidance of doubt, FHI Manufacturing Technology or Improvements thereto shall only include the Information or Improvements arising under any CVT Manufacturing Contracts or FHI Manufacturing
Contracts that are developed prior to FDA approval of the first NDA for the first Licensed Product hereunder or, as to Information or Improvements developed while preparing, conducting or completing the Validation Package, that have been developed
as of completion of said Validation Package activities, irrespective of whether the timing of completion is before or after the receipt of FDA approval of the first NDA for the first Licensed Product.” 
  
 12. Paid by CVT. A new Section 1.57 of the Agreement is hereby added as follows:

  
 “1.57 “Paid by CVT” shall mean with
respect to any CVT Manufacturing Activities or any FHI Manufacturing Activities, that (A) CVT has contributed its twenty five percent (25%) share of Development Cost payments under Sections 3.4(c)(i) or (ii); or (B) FHI may deduct twenty five
percent (25%) of the Cost of Goods under Section 3.4(c)(ii); or (C) CVT under said Section 3.4(c)(ii) does not owe its share because the Validation Batches or other batches could be and were sold commercially.” 
  
 13. Validation Batches. A new Section 1.58 of the Agreement is hereby added as
follows: 
  
 “1.58 “Validation Batch(es)”
shall have the meaning ascribed in Section 3.4(c)(ii).” 

 14. Validation Package. A new Section 1.59 of the Agreement is hereby added as follows: 
  
 “1.59 “Validation Package” shall mean the validation
of the manufacturing process for the first Licensed Product for the first NDA, including, without limitation, preparation of validation protocols and process documentation, the manufacture of validation batches and associated batch records, and any
and all validation reports and other validation-associated documentation, including any of the foregoing that is included in the first NDA for the first Licensed Product.” 
  
 15. CVT Manufacturing Activities. Section 3.4(a) of the Agreement is hereby amended to revise the definition of CVT Manufacturing
Activities to read as follows: 
  
 “As used herein,
“CVT Manufacturing Activities” shall mean: (i) CVT’s activities in identifying, selecting, qualifying and entering into definitive agreement(s) with Third Party(ies) to manufacture clinical supplies of Licensed Compounds and
Licensed Products and to supply raw materials and components for clinical supplies of Licensed Compounds and Licensed Products; and (ii) CVT’s activities in support of FHI Manufacturing Activities, including in connection with process
development and scale up work, preparation of primary stability lots and registration batches, the Validation Package, and other CVT activities in support of FHI Manufacturing Activities by FHI (on its own and with Third Parties under FHI
Manufacturing Contracts) under the Agreement.” 
  
 16. FHI Manufacturing
Activities. Section 3.4(a) of the Agreement is hereby further amended to revise the definition of FHI Manufacturing Activities to read as follows: 
  
 “As used herein, “FHI Manufacturing Activities” shall mean FHI’s activities up to and in connection with FDA approval of the
first NDA for the first Licensed Product hereunder, in accordance with the timeline(s) and transition plan to be determined by the Management Committee as provided above, to: (i) identify, select, qualify and enter into definitive agreement(s) with
Third Party(ies) to contract manufacture commercial supplies of Licensed Compounds and Licensed Products and to supply raw materials and components for commercial supplies of Licensed Compounds and Licensed Products; and (ii) to conduct process
development and scale up work to develop a commercial process for the manufacture and supply of Licensed Compounds and Licensed Products, including, without limitation, related analytical and stability work and the Validation Package. For avoidance
of doubt, FHI Manufacturing Activities shall specifically include FHI’s activities in securing additional sources for commercial supplies of Licensed Compound and Licensed Products.” 
  
 17. CVT Reimbursement of FHI. Section 3.4 (c) of the Agreement respecting CVT’s
responsibility to reimburse FHI for a portion of FHI Development Costs is hereby amended to become Section 3.4(c)(i), and to add the following new Section 3.4(c)(ii) which reads as follows: 
  
 “(ii) Notwithstanding the foregoing in Section 3.4(c)(i), financial
responsibility for FHI’s Development Costs related to manufacturing Validation Batches (defined 

 below) shall be allocated as follows: FHI shall be responsible for one hundred percent (100%) of the Cost
of Goods (defined below) of all such batches that could by sold by FHI commercially. CVT shall be responsible for twenty-five percent (25%) of the Cost of Goods of all such batches that could not be sold by FHI commercially. FHI shall pay at the
time of manufacture (i) one hundred percent (100%) of the Cost of Goods for batches that the Management Committee assesses could be sold commercially, and (ii) seventy five percent (75%) of the Cost of Goods for batches that the Management Committee
assesses could not be sold commercially; and in the event that batches for which FHI previously paid one hundred percent (100%) were not sold commercially ten (10) months prior to the expiration of the approved shelf life, FHI may deduct CVT’s
twenty-five percent (25%) allocation of such Cost of Goods from royalty and milestone payments owed under Article 5 or other monies that FHI may owe CVT hereunder. As for FHI’s Development Costs other than Cost of Goods relating to Validation
Batches, CVT shall be responsible for paying its twenty-five percent (25%) share of FHI’s Development Costs as and when specified in Section 3.4(c)(i). As used herein, “Validation Batch(es)” means commercial-scale batches that
are manufactured for the purpose of obtaining a Regulatory Approval for a Licensed Product in the Development Field in the United States. As used herein “Cost of Goods” means that portion of FHI’s Development Costs representing
(i) if manufactured by FHI, the directly allocable out-of-pocket costs for raw materials and components used in the manufacture of Validation Batches, as well as FTE Charges and any other labor charges directly resulting from the manufacture of
Validation Batches; and (ii) if manufactured by a Third Party, the actual invoiced price for manufacture of such Validation Batches.” 
  
 18. FHI Manufacturing Contracts. A new Section 3.4(d) of the Agreement relating to FHI Manufacturing Contracts is hereby added as follows:  
  
 “(d) FHI hereby covenants and agrees as follows with respect to all
contracts that it enters into with Third Parties relating to the manufacture of Licensed Compounds or Licensed Products, including for commercial scale manufacture of drug substance, drug product or finished Licensed Products during the Term
(collectively, “FHI Manufacturing Contracts”): 
  
 (i) FHI will not enter into FHI Manufacturing Contracts that would contradict the terms of the Agreement or prevent CVT from having access to and the right to use FHI Manufacturing Technology and Improvements thereto Controlled by FHI, as
provided in the Agreement. In addition, FHI will not enter into any FHI Manufacturing Contract with a Third Party that contains any exclusivity provisions that would prevent CVT from also contracting with such Third Party consistent with CVT’s
license rights under Section 8.2(b)(i) below for the manufacture and supply of Licensed Compounds and/or Licensed Products using FHI Manufacturing Technology and Improvements thereto Controlled by FHI, as the same have been licensed by FHI to CVT
under Section 8.2(b)(i) of the Agreement. 

 (ii) Subject to any confidentiality restrictions set forth in such FHI Manufacturing Contracts, FHI will
provide CVT with the name(s) and address(es) of the Third Party(ies) who are manufacturing and supplying Licensed Compounds to FHI under such FHI Manufacturing Contracts.” 
  
 19. CVT Manufacturing Contracts. A new Section 3.4(e) of the Agreement relating to CVT Manufacturing Contracts is hereby added as
follows:  
  
 “(e) CVT hereby covenants and agrees as
follows with respect to all contracts that it enters into with Third Parties relating to the manufacture of Licensed Compounds or Licensed Products for commercial distribution outside the Territory, including for CVT Manufacturing Activities and for
commercial scale manufacture of drug substance, drug product or finished Licensed Products during the Term (collectively, “CVT Manufacturing Contracts”): 
  
 (i) CVT will not enter into CVT Manufacturing Contracts that would contradict the terms of the Agreement or prevent FHI from
having access to and the right to use Licensed Technology and Improvements thereto Controlled by CVT as provided in the Agreement. In addition, CVT will not enter into any CVT Manufacturing Contract with a Third Party that contains any exclusivity
provisions that would prevent FHI from also contracting with such Third Party consistent with FHI’s license rights under this Agreement for the manufacture and supply of Licensed Compounds and/or Licensed Products. 
  
 (ii) Subject to any confidentiality restrictions set forth in such FHI
Manufacturing Contracts, CVT will provide FHI with the name(s) and address(es) of the Third Party(ies) who are manufacturing and supplying Licensed Compounds to CVT under such CVT Manufacturing Contracts.” 
  
 20. Termination of CVT’s Royalty Obligations (if any). To the extent that CVT has
any obligation to FHI to pay royalties to FHI under Section 3.7 of the Agreement, relating to the use of the Collaborative Clinical Data and/or the FHI Clinical Data, the Parties agree that CVT’s royalty obligations shall expire at the same
time and in the same manner as the expiration of FHI’s royalty obligations under Section 5.5(b). 
  
 21. Records. Section 6.1 of the Agreement is hereby amended and restated as follows: 
  
 “Each Party shall keep or cause to be kept such records as are required to determine, in a manner consistent with generally accepted accounting
principles in the United States, any sums or credits due under this Agreement, including, but not limited to, Development Costs for CVT’s and FHI’s activities under the Development Plan (including FHI Manufacturing Activities that are Paid
by CVT), royalties, etc. At the 

 request (and expense) of either Party, the other Party and its Sublicensees (or sublicensees, in the case
of CVT) shall permit an independent certified public accountant appointed by such Party who shall be subject to the confidentiality restrictions set forth in Article 10 and reasonably acceptable to the other Party, at reasonable times not more than
once a year and upon reasonable notice, to examine only those records as may be necessary to determine, with respect to any calendar year ending not more than three (3) years prior to such Party’s request, the correctness or completeness of any
payment made under this Agreement. Such audit may occur more frequently than once per calendar year for good cause shown by the requesting Party due to legal or regulatory reasons. Results of any such examination shall be (a) limited to information
relating to the Licensed Compounds and Licensed Products, (b) made available to both Parties, and (c) deemed Confidential Information subject to Article 10. The Party requesting the audit shall bear the full cost of the performance of any such
audit, unless such audit discloses a variance of more than five percent (5%) from the amount of the original report, royalty or payment calculation. In such case, the Party being audited shall bear the full cost of the performance of such audit, as
well as promptly paying any shortfall reported and any interest due thereon. Any overpayments shall be promptly repaid, and any interest due thereon. In addition to the quarterly royalty reports and royalty payments under Section 5.7 above, FHI
shall provide CVT with a preliminary report of Net Sales and royalties owed thereon within five (5) business days after the end of each quarter. Such report shall be considered an estimate only. In connection with FHI’s royalty payments to CVT
under the Agreement and CVT’s royalty payments to FHI under the Agreement (for purposes of Section 3.7(e) and Section 8.2(b) only), and in connection with each Party’s reimbursement of Development Costs as provided under the Agreement,
each Party may reasonably request additional information from time to time, particularly to satisfy accounting, regulatory or legal requirements, including but not limited to under the Sarbanes Oxley Act of 2002, as amended, and all United States
Securities and Exchange Commission rules and regulations relating thereto.” 
  
 22. Licenses to CVT. Section 8.2 of the Agreement is hereby amended and restated as follows:  
  
 “8.2 Licenses to CVT. FHI and CVT hereby agree on the following license rights to CVT to use the FHI Development Technology (as defined
in Section 1.17), including, without limitation, the Collaborative Clinical Data in the FHI Field, the FHI Clinical Data in the Development Field and the FHI Manufacturing Technology: 
  
 (a) As provided in Section 3.7 above, FHI hereby grants to CVT an exclusive (except as to FHI and FHI Affiliates) license
(with the right to sublicense) to use the Collaborative Clinical Data in the FHI Field and the FHI Clinical Data in the Development Field outside of the Territory to develop, make, have made, use, market, export and import any pharmaceutical
products (including any Licensed Products), in consideration for CVT’s payment to FHI of the royalty provided in Section 3.7 above. 

 (b) (i) FHI hereby grants to CVT an exclusive (except as to FHI and FHI Affiliates) license (with the
right to sublicense) to use FHI Manufacturing Technology and Improvements thereto that are Controlled by FHI in the Development Field to develop, make, have made, use, market, export and import any pharmaceutical products (including any Licensed
Products) outside of the Territory. In addition, FHI hereby grants to CVT a non-exclusive license to use FHI Manufacturing Technology and Improvements thereto that are Controlled by FHI in the Development Field to develop, make, have made, use
(other than for marketing or sale), and export any pharmaceutical products (including any Licensed Products) inside the Territory, but only to in connection with and in support of CVT’s exclusive license under the preceding sentence of this
Section 8.2(b)(i). As consideration for such licenses, CVT shall pay FHI a royalty of [*] of all Net Sales by CVT and its Affiliates, sublicensees, and distributors of Licensed Products (or where CVT has assigned its rights to sell Licensed Products
to Third Parties, by such Third Parties). Once the aggregate total of (A) CVT’s royalty payments under this Section 8.2(b), (B) all Development Costs Paid by CVT for FHI Manufacturing Activities under Section 3.4(c)(i), and (C) all Cost of
Goods Paid by CVT, is equal to [*], then CVT’s royalty obligation under this Section shall cease and CVT’s license rights hereunder shall be fully-paid up and (where FHI’s own rights to such FHI Manufacturing Technology and
Improvements thereto so permit) exclusive (except as to FHI and FHI Affiliates), irrevocable and perpetual with the right to sublicense. In order to track CVT’s royalty obligations and the cap amount hereunder, FHI shall provide quarterly
reports to CVT of the aggregate total of Development Costs incurred by FHI for such FHI Manufacturing Activities, and the total amount of such costs reimbursed by CVT under Section 3.4(c)(i), through the reporting date. 
  
 (ii) The provisions of Sections 5.7, 5.9-5.13, and 6.1 of
the Agreement shall also apply to CVT’s royalty payment obligations under this Section 8.2 (b). 
  
 (c) FHI hereby grants to CVT an exclusive (except as to FHI and FHI Affiliates) royalty-free license (with the right to sublicense) to use
and practice all other FHI Development Technology Controlled by FHI (other than the Collaborative Clinical Data, the FHI Clinical Data, the FHI Manufacturing Technology, and Improvements to any of the foregoing) outside of the Territory to develop,
make, have made, use, market, sell, export and import any pharmaceutical products (including any Licensed Products). 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 (d) In the event CVT exercises its right to convert the licenses granted to FHI hereunder from exclusive
to co-exclusive under Section 4.4 above, FHI automatically shall be deemed to grant to CVT a co-exclusive (with FHI and FHI Affiliates) license (with right to sublicense) to use any and all FHI Development Technology Controlled by FHI to use,
market, sell, export, and import any Licensed Product inside the Territory, where FHI’s own rights to such FHI Development Technology so permit. 
  
 (e) In connection with the termination of the Agreement (if any), FHI shall automatically grant CVT an exclusive (except as to FHI and FHI Affiliates)
license (with the right to sublicense) to use any and all FHI Development Technology Controlled by FHI as provided in Section 12.6(b) below, where FHI’s own rights to such FHI Development Technology so permit.” 
  
 23. Effect of Termination. Section 12.6(b) of the Agreement is hereby amended and
restated as follows: 
  
 “(b) Subject to Section 12.6(e)
below, FHI automatically shall be deemed to have granted to CVT an exclusive (except as to FHI and FHI Affiliates), irrevocable, perpetual, license with the right to sublicense under the Collaborative Clinical Data in the FHI Field, the FHI Clinical
Data in the Development Field, the FHI Manufacturing Technology and under any other FHI Development Technology Controlled by FHI (where FHI’s own rights to such FHI Development Technology so permit), to develop, use, make, have made, import,
offer for sale and sell Licensed Compounds, Licensed Products and any other pharmaceutical products worldwide; provided, however, that if CVT terminates this Agreement pursuant to Section 12.3, then the foregoing grant of license rights from FHI to
CVT shall apply only to the particular Licensed Product for the particular indication in the particular country that was the subject of such termination.” 
  

24. Notices. Section 15.3 of the Agreement is hereby amended to change the mailing addresses of the Parties as follows: 
  

			
	“For CVT:	  	CV Therapeutics, Inc.
	 	  	3172 Porter Drive
	 	  	Palo Alto, CA 94304
	 	  	Attn: Chief Executive Officer
	 	  	With a copy to: General Counsel
	 	  	Telephone: (650) 384-8611
	 	  	Telecopy: (650) 858-0388
		
	With a copy to:	  	Latham & Watkins LLP
	 	  	135 Commonwealth Avenue
	 	  	Menlo Park, CA 94025
	 	  	Attn: Alan C. Mendelson, Esq.
	 	  	Telephone: (650) 463-4693
	 	  	Telecopy: (650) 463-2600

			
	For FHI:	  	Astellas US LLC
	 	  	Three Parkway North Center
	 	  	Deerfield, IL 20015
	 	  	Attn: General Counsel
	 	  	With a copy to: the Chief Executive Officer,
	 	  	              the Senior Vice President of Finance, and
	 	  	              the Executive Vice President
	 	  	Telephone: (847) 317-8870
	 	  	Telecopy: (847) 317 7288”

  
 25. No Other Modifications. In
all other respects, the Agreement’s terms and conditions shall remain unchanged and in full force and effect. In the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall
govern. 
  
 IN WITNESS WHEREOF, the Parties have executed this Amendment by their
duly authorized officers as of the date set forth above. 
  

							
	Astellas US LLC	 	CV Therapeutics, Inc.
				
	By:	 	 /s/ M. Nishimura, Ph.D.

	 	By:	 	 /s/ Louis G. Lange, M.D., Ph.D.

	Name:	 	M. Nishimura, Ph. D.	 	Name:	 	Louis G. Lange, M.D., Ph. D.
	Title:	 	President & CEO	 	Title:	 	Chairman of the Board & CEO
	Date:	 	August 30, 2005	 	Date:	 	August 30, 2005

 Amended and Restated Schedule 1.10 
 Designated Patents 
  
 The Designated Patents include the following patent applications/patents entitled: 
  

	(1)	“N-Pyrazole A2A Receptor Agonists”

  

							
	 Country

	  	 Application #:

	  	 Title

	  	Patent #:

	 Patent Cooperation Treaty
	  	 PCT/US00/40281
	  	N-PYRAZOLE A2A RECEPTOR AGONISTS	  	 
				
	 Canada
	  	 2,377,746
	  	N-PYRAZOLE A2A RECEPTOR AGONISTS	  	 
				
	 Mexico
	  	 2001-013325
	  	AGONISTAS DEL RECEPTOR N-PIRAZOL A2A	  	 
				
	 USA
	  	 09/338,185
	  	N-PYRAZOLE A2A ADENOSINE RECEPTOR AGONISTS	  	6,403,567
				
	 USA
	  	 10/018,446
	  	2-(N-PYRAZOLO)ADENOSINES WITH APPLICATION AS ADENOSINE A2A RECEPTOR AGONISTS	  	6,642,210
				
	 USA
	  	 10/652,378
	  	N-PYRAZOLE A2A RECEPTOR AGONISTS	  	 

  

	(2)	“C-Pyrazole A2A Receptor Agonists”

  

							
	 Country

	  	 Application #:

	  	 Title

	  	Patent #:

	 Patent Cooperation Treaty
	  	PCT/US00/17095	  	C-PYRAZOLE A2A RECEPTOR AGONISTS	  	 
				
	 Canada
	  	2,375,430	  	C-PYRAZOLE A2A RECEPTOR AGONISTS	  	 
				
	 Mexico
	  	2001-013350	  	AGONISTAS DEL RECEPTOR C-PIRAZOL A2A	  	 
				
	 USA
	  	09/338,327	  	C-PYRAZOLE A2A RECEPTOR AGONISTS	  	6,214,807
				
	 USA
	  	09/812,176	  	C-PYRAZOLE A2A RECEPTOR AGONISTS	  	6,855,818
				
	 USA
	  	10/018,758	  	C-PYRAZOLE A2A RECEPTOR AGONISTS	  	6,770,634
				
	 USA
	  	10/813,535	  	C-PYRAZOLE A2A RECEPTOR AGONISTS	  	 

	(3)	“Partial A2A Adenosine Receptor
Agonists” 

  

							
	 Country

	  	 Application #:

	  	 Title

	  	Patent #:

	 Patent Cooperation Treaty
	  	 PCT/US01/005831
	  	IDENTIFICATION OF PARTIAL AGONISTS OF THE A2A ADENOSINE RECEPTOR	  	 
				
	 Canada
	  	 2,439,222
	  	DENTIFICATION OF PARTIAL AGONISTS OF THE A2A ADENOSINE RECEPTOR	  	 
				
	 USA
	  	 60/184,296
	  	PARTIAL A2A ADENOSINE RECEPTOR (ADOR) AGONIST	  	N/A
				
	 USA
	  	 60/219,876
	  	LOW AFFINITY A2A RECEPTOR AGONISTS	  	N/A
				
	 USA
	  	 09/792,617
	  	METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2A RECEPTOR	  	N/A
				
	 USA
	  	 10/614,702
	  	METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2A RECEPTOR	  	N/A
				
	 USA
	  	 11/070,768
	  	MYOCARDIAL PERFUSION IMAGING METHOD	  	 

  

	(4)	“Myocardial Perfusion Imaging Method” 

  

							
	 Country

	  	 Application #:

	  	 Title

	  	Patent #:

	 Patent Cooperation Treaty
	  	 PCT/US03/023511
	  	MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	  	 
				
	 Canada
	  	 2,492,855
	  	MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	  	 
				
	 Mexico
	  	 2005-001123
	  	FORMACIÓN DE IMAGINES POR PERFUSION DE MIOCARDIO MEDIANTE EL USO DE AGONISTAS RECEPTORS DE A2A	  	 
				
	 USA
	  	 60/399,176
	  	MYOCARDIAL PERFUSION IMAGING AGENT	  	N/A
				
	 USA
	  	 60/399,177
	  	LOW DOSAGE MYOCARDIAL PERFUSION IMAGING AGENT	  	N/A
				
	 USA
	  	 60/426,902
	  	LOW DOSAGE MYOCARDIAL PERFUSION IMAGING AGENT	  	N/A
				
	 USA
	  	 60/459,803
	  	MYOCARDIAL PERFUSION IMAGING METHOD	  	N/A
				
	 USA
	  	 10/629,368
	  	MYOCARDIAL PERFUSION IMAGING METHOD	  	 
				
	 USA
	  	 10/766,403
	  	MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS	  	 
				
	 Patent Cooperation Treaty
	  	 PCT/US04/02304
	  	MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS	  	 

	(5)	“Use of A2A Adenosine Receptor Agonists” 

  

							
	 Country

	  	Application #:

	  	 Title

	  	Patent #:

	 USA
	  	60/620,577	  	USE OF A2A ADENOSINE RECEPTOR AGONISTS	  	 

  

	(6)	[*] 

  

							
	 [*]
	 	[*]	 	 [*]
	  	[*]
				
	 [*]
	 	 [*]
	 	 [*]
	  	 

  

	(7)	“Method of Preventing Reperfusion Injury” 

  

							
	 Country

	  	Application #:

	  	 Title

	  	Patent #:

	 USA
	  	09/848,809	  	METHOD OF PREVENTING REPERFUSION INJURY	  	6,599,283

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 New Schedule 1.29 
 Chemical Names and Structures of Licensed Compounds 
  
 CVT-3146: 
  
 

 
  
 known as (1-{9-[(4S, 2R, 3R,
5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and identified by the Chemical Abstracts Service Registry Number 313348-27-5. 
  
 [*] 
  
 

 
  
 known as (4S, 2R, 3R,
5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol, and identified by the Chemical Abstracts Service Registry Number 313350-86-6. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]